LSTA
Lisata Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.67 / 10
Netural
Analyst sentiment is neutral with no coverage bias (Neutral: 100%). Fund-flow metrics are strong (7.34/10) but exhibit negative trends across all size brackets (overall, block, small, medium, large, extra-large), hinting at capital outflows despite the high score. This divergence underscores the importance of tracking liquidity changes.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-21
InstitutionBrookline Capital
Times predicted2
Historical Win Rate0.0%
What is the analyst consensus for LSTA?
- LSTA holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.67/10 (Netural).
